Overview
- Net revenue rose 9.1% to $15.78 billion, led by immunology sales of $7.89 billion as Skyrizi climbed 46.8% to $4.71 billion and Rinvoq rose 35.3% to $2.18 billion, while Humira fell 55.4% to $993 million.
- Neuroscience revenue grew 20.2% to $2.84 billion, including $985 million for Botox Therapeutics and $934 million for Vraylar.
- Adjusted EPS was $1.86, down 38% year over year but above the $1.79 consensus.
- GAAP diluted EPS was $0.10, reflecting acquired IPR&D and milestone charges that the company says total $2.05 per share year-to-date within guidance.
- AbbVie raised its 2025 adjusted EPS guidance to $10.61–$10.65 and increased the quarterly dividend to $1.73 per share, while the stock traded down roughly 3–4%.